Cargando…

Romidepsin targets multiple survival signaling pathways in malignant T cells

Romidepsin is a cyclic molecule that inhibits histone deacetylases. It is Food and Drug Administration-approved for treatment of cutaneous and peripheral T-cell lymphoma, but its precise mechanism of action against malignant T cells is unknown. To better understand the biological effects of romideps...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valdez, B C, Brammer, J E, Li, Y, Murray, D, Liu, Y, Hosing, C, Nieto, Y, Champlin, R E, Andersson, B S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635192/ https://www.ncbi.nlm.nih.gov/pubmed/26473529 http://dx.doi.org/10.1038/bcj.2015.83

Ejemplares similares

Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy
por: Valdez, Benigno C., et al.
Publicado: (2016)

Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines
por: Valdez, B C, et al.
Publicado: (2014)

Romidepsin-induced neutrophilic urticaria
por: Scott, Brian, et al.
Publicado: (2016)

Romidepsin in the treatment of cutaneous T-cell lymphoma
por: Jain, Salvia, et al.
Publicado: (2011)

Romidepsin for the Treatment of Peripheral T-Cell Lymphoma
por: Barbarotta, Lisa, et al.
Publicado: (2015)

Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells
por: Valdez, Benigno C., et al.
Publicado: (2017)

Pharmacokinetics and Immunological Effects of Romidepsin in Rhesus Macaques
por: Kleinman, Adam J., et al.
Publicado: (2020)

Immunosuppression-associated primary cutaneous plasmablastic lymphoma secondary to romidepsin
por: Costello, Collin M., et al.
Publicado: (2019)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
por: Søgaard, Ole S., et al.
Publicado: (2015)

Deciphering the molecular effects of romidepsin on germ cell tumours: DHRS2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectors
por: Nettersheim, Daniel, et al.
Publicado: (2018)

Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
por: Foss, Francine, et al.
Publicado: (2014)

Romidepsin Controls Chronic Lymphocytic Leukemia in a Patient with Mycosis Fungoides
por: Lemchak, David. M., et al.
Publicado: (2016)

Romidepsin suppresses monosodium urate crystal-induced cytokine production through upregulation of suppressor of cytokine signaling 1 expression
por: Cleophas, M. C. P., et al.
Publicado: (2019)

The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis
por: Conforti, Franco, et al.
Publicado: (2017)

Long-Term Treatment with Romidepsin in Patients with Peripheral T-Cell Lymphoma
por: Irlé, Claudius, et al.
Publicado: (2016)

Synergistic Effect of Simvastatin and Romidepsin on Gamma-globin Gene Induction
por: Habibi, Hussain, et al.
Publicado: (2019)

Simvastatin-romidepsin combination kills bladder cancer cells synergistically
por: Okubo, Kazuki, et al.
Publicado: (2021)

Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies
por: Lekakis, L, et al.
Publicado: (2006)

Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T‐cell lymphoma
por: Pro, Barbara, et al.
Publicado: (2016)

A5 Peripheral blood cells contribute to HIV-1 viremia induced by romidepsin
por: Winckelmann, A., et al.
Publicado: (2017)

Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin
por: Sager, Philip T, et al.
Publicado: (2015)

Use of class I histone deacetylase inhibitor romidepsin in combination regimens
por: Petrich, Adam, et al.
Publicado: (2016)

Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T‐cell lymphoma
por: Foss, Francine, et al.
Publicado: (2016)

Romidepsin Induces G2/M Phase Arrest and Apoptosis in Cholangiocarcinoma Cells
por: Li, Pihong, et al.
Publicado: (2020)

Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma
por: Pattarawat, Pawat, et al.
Publicado: (2020)

P1195: A REAL WORLD EXPERIENCE OF COMBINED TREATMENT WITH ROMIDEPSIN AND AZACITIDINE IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA.
por: Kalac, M., et al.
Publicado: (2022)

Romidepsin inhibits Ras-dependent growth transformation of NIH 3T3 fibroblasts and RIE-1 epithelial cells independently of Ras signaling inhibition
por: Hanker, Ariella B, et al.
Publicado: (2009)

Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers
por: Policicchio, Benjamin B., et al.
Publicado: (2016)

Augmented efficacy with the combination of blockade of the NOTCH-1 pathway, Bortezomib and Romidepsin in a murine MT-1 adult T cell leukemia model
por: Yu, Ping, et al.
Publicado: (2014)

Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma
por: Kim, Ellen J., et al.
Publicado: (2015)

Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma
por: Poligone, Brian, et al.
Publicado: (2011)

Induction of MAPK- and ROS-dependent autophagy and apoptosis in gastric carcinoma by combination of romidepsin and bortezomib
por: Hui, Kwai Fung, et al.
Publicado: (2015)

Crosstalk among the proteome, lysine phosphorylation, and acetylation in romidepsin-treated colon cancer cells
por: Wang, Tian-Yun, et al.
Publicado: (2016)

Successful response with romidepsin in relapsed peripheral T-cell lymphoma, not otherwise specified with leukemic progression
por: Sato, Shuku, et al.
Publicado: (2020)

HDAC1/2 Inhibitor Romidepsin Suppresses DEN-Induced Hepatocellular Carcinogenesis in Mice
por: Afaloniati, Hara, et al.
Publicado: (2020)

Complete response to romidepsin as monotherapy in treatment-resistant subcutaneous panniculitis-like T-cell lymphoma
por: Jothishankar, Balaji, et al.
Publicado: (2020)

Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma
por: Kalac, Matko, et al.
Publicado: (2023)

R-Loop–Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin
por: Safari, Maryam, et al.
Publicado: (2021)

Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin
por: Cruickshank, M N, et al.
Publicado: (2017)

A novel angiogenesis inhibitor impairs lovo cell survival via targeting against human VEGFR and its signaling pathway of phosphorylation
por: Zhang, Y M, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_hplqs84tlnouk9p34fjbcm2sv8